News

BDI’s portfolio includes branded and generic specialty pharmaceuticals, chemotherapy products, vaccines, albumin, IVIG, coagulation factors, high-titer or hyper immune globulins and other specialty injectables. BDI IT VP Tim

The patented, gene expression test uses a simple, noninvasive method of blood sample collection and can show the low probability of acute cellular rejection in stable heart transplant

The addition of MedAppz’ iSuite EHR broadens MedLink’s technology offerings, enabling the company to provide a web-based solution built on the latest Microsoft .Net 4.0 platform. MedAppz claims

Mitsui has invested $12.5m in cash in return for new convertible Preference Shares giving Mitsui 12.2% of the enlarged share capital of Hutchison MediPharma. Mitsui Global Investment Department

GLG Pharma said that the proceeds of the grant will be used to advance the development of three product candidates, GLG-202, GLG-302, GLG-401, all STAT3 inhibitors, representing a

Accoding to Affymax, the decrease in revenue was the result of decreased collaboration revenue, driven primarily by lower reimbursement of clinical trial expenses, from its collaboration with Takeda

EnVivo claimed that, by acting as a co-agonist and sensitising the alpha-7 receptor, EVP-6124 makes it possible for smaller amounts of naturally occurring ACh, typically found in individuals

The certification covers single-dose and multiple-dose toxicology studies in both rodents and non-rodents, GeneTox studies (Ames, micronucleus, and chromosome aberration), and toxicokinetic studies. According to WuXi PharmaTech, the

Halozyme has posted a net loss of $12.4m for the third quarter 2010, or $0.13 loss per diluted share, compared to net loss of $13.91m, or $0.16 loss